Powered by
Corbus Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update
Mar 9, 2017 - Marketwire (Canada)

NORWOOD, MA--(Marketwired - March 09, 2017) -

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today its financial results for the year ended December 31, 2016.

The Company also provided an update to its corporate progress, clinical status and anticipated milestones for JBT-101 ("Resunab"), its novel synthetic oral endocannabinoid-m

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox